Hard To Treat Diseases (HTDS.PK) Scientists report results that are encouraging for the future of Multiple Sclerosis Treatment

BELGRADE, Serbia, June 3 /PRNewswire-FirstCall/ - Hard to Treat Diseases, Inc. (HTDS:PK), http://www.htdsmedical.com announced today that researchers from its Slavica BioChem (www.slavicabiochem.com) division in Belgrade made a great progress in the experimental findings to aid in the suppression or ultimately cure of Multiple Sclerosis which are comparable with investigations of other MS-Research groups around the world.

In a recent press release posted on May 24, 2010 Abbott, and Biogen Idec. announced enrollment of the first patient in a global Phase III study evaluating the efficacy and safety of daclizumab compared to interferon beta-1a (AVONEX(R)) in patients with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS), one of the most common neurological disorders that affects more than 2.5 million people worldwide.

This study is based on investigations of researchers from University Hospital, Basel, Switzerland. Dr Ludwig Kappos, M.D., Head, MS-Research Group, and lead investigator for the study said: "As shown in previous studies, daclizumab appears to selectively target immune cells that are thought to become activated in MS and cause damage to the central nervous system. Daclizumab is a humanized monoclonal antibody that binds to CD25, a receptor subunit that is expressed at low levels on resting T-cells and at high levels on T-cells that are thought to become activated in response to MS. Daclizumab is believed to work by selectively targeting these activated T-cells without causing general T-cell depletion leading to reduction in the number of new or enlarged MS lesions."

Researchers in Belgrade are also making progress in suppression of immune response in MS using another immunomodulatory approach that involved application of purine nucleoside analogues: Ribavirin (FDA approved drug used in human clinical practice for 20 years) and Tiazofurin (orphan-drug). These drugs act primarily by inhibition of Inosine Monophosphate Dehydrogenase (IMPDH), a rate limiting enzyme in de novo purine synthesis pathway causing interruption of cell metabolism. Importantly, this exhaustion of purine pools had a more potent effect on activated lymphocytes than on the other cell types, since salvage pathways for the production of guanine nucleosides do not operate in T- and B cells. In this way, Ribavirin and Tiazofurin also work by selectively targeting activated T-cells. Prof Mirjana Stojiljkovic, the leader of IBISS research team, and Medical Advisor of Slavica BioChem division said: "We have shown promising results in decreasing severity of clinical symptoms and duration of MS induced in experimental animals, and radical reduction of mortality and degree of disability. Administration of ribavirin and tiazofurin attenuated proliferation of autoreactive T lymphocytes and their infiltration into the nervous tissue, and thereby prevented myelin destruction. Similarly to our colleagues from Switzerland we have observed that the severity of treatment side effects of used substances was low and disappeared after cessation of drug application. These results are encouraging for the future of MS therapy."

For any matters relating to retail investor queries or to send the company or its IR a message please click on the "INVESTOR SUPPORT" TAB, or the direct link http://www.minamargroup.net/helpdesk.

Don't be a victim. Report a stock basher to authorities. The company is mindful that short sellers, the company competitors and stock bashers stalk small cap Pink Sheets listed companies with hidden agendas. Visit http://www.stockbasher.com/ and find out what criminal and civil actions the US authorities are taking against web sites and the remedies available to you as an individual investor. Discover for yourself why and how USA based small businesses and the backbone of the economy suffer. Stay informed and do not allow entrepreneurs dreams, innovations, and their access to capital to be thwarted as "scalpers" and day traders vigorously day in and day out try to exploit and extinguish US innovation and progress for quick profits.

Filings for this event are currently being reviewed and will be filed with Pink Sheets and Client Support section in due course. To be included in company's email database for press releases, industry updates, and non-weekly activity in the company that may or may not be news released, please subscribe or opt in mailer at http://www.minamargroup.com/updates.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact [email protected]; for any corporate matters, please contact [email protected], www.htdsmedical.com

SOURCE Hard to Treat Diseases